Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Wider window for starting alteplase after stroke gets nod from NICE

News team

Alteplase has been approved for use within its extended time window for initiating treatment after stroke in guidance published today by the National Institute for Health and Clinical Excellence (26 September 2012).

The document updates NICE’s 2007 guidance on the use of alteplase (Actilyse; Boehringer Ingelheim) for treating acute ischaemic stroke, to reflect a recent licensing change that widened the window for beginning treatment from three hours to four and a half hours.

NICE says treatment must be started as early as possible after the onset of stroke symptoms, and after intracranial haemorrhage has been excluded using the appropriate imaging techniques.

Carole Longson, director of the NICE Health Technology Evaluation Centre, stressed that the benefits of alteplase treatment "can only be realised if brain imaging to confirm a diagnosis of acute ischaemic stroke is received as soon as possible, and certainly within one hour of arrival at the hospital, as per the NICE Quality Standard for stroke".

The Scottish Medicines Consortium approved alteplase’s extended treatment window for stroke in June 2012 (PJ 2012;288:702).

Citation: The Pharmaceutical Journal URI: 11107288

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • (Cosmin Constantin Sava/Dreamstime.com)

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.